Elecsys CMV IgGRecalls & reported problems across all models
Roche Diagnostics GmbH · 2 models in the FDA device registry
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 51
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls
- 0
We found 2 models of Elecsys CMV IgG by Roche Diagnostics GmbH in the FDA's device registry (GUDID). Together they are named in 51 adverse event reports in the FDA's MAUDE database, received between Aug 23, 2021 and Aug 12, 2026 — classified as 1 injury, 50 malfunctions.
The most frequently reported specific device problem is “Low Test Results” (21 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event. Widely used products collect more reports, so totals can't be used to compare products or estimate failure rates. Only reports that name a model's exact device identifier are counted. What reports can and can't tell you · How this data works
Reports received per month, all models
Most reported Elecsys CMV IgG problems
Device problems
- Low Test Results21
- High Test Results16
- False Negative Result12
- False Positive Result7
- Non Reproducible Results7
- Incorrect, Inadequate or Imprecise Result or Readings1
Patient problems
- No Clinical Signs, Symptoms or Conditions51
Elecsys CMV IgG models
2 models, most reported first. Each model has its own page with its reports, recalls and device details.
- Elecsys CMV IgG 09118551190ENZYME LINKED IMMUNOABSORBENT ASSAY, CYTOMEGALOVIRUS43 reports
- Elecsys CMV IgG 07027117190ENZYME LINKED IMMUNOABSORBENT ASSAY, CYTOMEGALOVIRUS8 reports
Recent Elecsys CMV IgG adverse event reports
The 15 most recent reports across all models, in the reporter's own words as published by the FDA.
MalfunctionAug 12, 2026False Positive Result
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 50226289 ↗MalfunctionAug 12, 2026Low Test Results
There was an allegation of questionable Elecsys CMV IgG and Elecsys CMV IgM results for 1 patient on a cobas e 801 analytical unit compared to a Vidas analyzer.This Medwatch will cover CMV IgG. Refer to Medwatch with A1 patient identifier (b)(6) for information on the CMV IgM results.On (b)(6) 2025, the patient had a CMV IgG result of 0.38 U/mL (negative) and a CMV IgM result of 0.69 COI (negative).On (b)(6) 2026, the patient had a CMV IgG result of 3.68 U/mL (positive) and a CMV IgM result of 0.657 COI (negative).On (b)(6) 2026, the customer repeated the previous patient samples.The sample from on (b)(6) 2025 gave a CMV IgG result of 0.37 U/mL (negative) and a CMV IgM result of 0.789 COI (equivocal).The sample was also sent to another laboratory and tested on a Vidas analyzer and the CMV IgG result was 20 (positive) and the CMV IgM result was 33.6 (positive).The sample from on (b)(6) 2026 gave a CMV IgG result of 3.69 U/mL (positive) and a CMV IgM result of 0.718 COI (equivocal).The sample was also sent to another laboratory and tested on a Vidas analyzer and the CMV IgG result was 19 (positive) and the CMV IgM result was 24 (positive).The Vidas analyzer results units of measureme
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 50224800 ↗MalfunctionAug 6, 2026False Positive Result; Non Reproducible Results
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 50161483 ↗MalfunctionJul 16, 2026False Negative Result
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 25835832 ↗InjuryMay 13, 2026High Test Results
THERE WAS AN ALLEGATION OF A QUESTIONABLE ELECSYS CMV IGG RESULT FOR 1 PATIENT SAMPLE ON A COBAS E 801 ANALYTICAL UNIT COMPARED TO A DIASORIN ANALYZER. FOR INFORMATION RELATED TO THE CMV IGM ASSAY, PLEASE REFER TO MFG REPORT 1823260-2026-01549 THIS MDR IS BEING SUBMITTED IN AN ABUNDANCE OF CAUTION. ON (B)(6) 2025, THE CMV IGM RESULT WAS 0.48 IU/ML (NEGATIVE) AND THE CMV IGG RESULT WAS 3.91 IU/ML (POSITIVE). THE PATIENT WAS 9 WEEKS AND 2 DAYS PREGNANT, AND THE RESULTS INDICATED CMV IMMUNITY. WHEN THE PATIENT WAS 22 WEEKS PREGNANT, SEVERE FETAL BRAIN ABNORMALITIES WERE DETECTED SUGGESTING FETAL CYTOMEGALOVIRUS INFECTION. AMNIOCENTESIS WAS PERFORMED AND CMV PCR IN AMNIOTIC FLUID GAVE A POSITIVE RESULT, CONFIRMING FETAL CMV INFECTION. THE SEVERITY OF THE BRAIN LESIONS WAS CONFIRMED BY MRI OF THE FETAL BRAIN AND TERMINATION OF PREGNANCY WAS PERFORMED. THE PATIENT SAMPLE FROM (B)(6) 2025 WAS RETESTED ON A DIASORIN ANALYZER AND THE CMV IGM RESULT WAS 51.7 IU/ML (POSITIVE) AND THE CMV IGG RESULT WAS <5 IU/ML (NEGATIVE). THE EXACT DATE OF TESTING WAS NOT PROVIDED. ON (B)(6) 2026, THE SAMPLE FROM (B)(6) 2025 WAS REPEATED ON LINE 1 OF THE COBAS ANALYZER AND THE CMV IGM RESULT WAS 0.51 (NEGATI
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 25163961 ↗MalfunctionApr 8, 2026Non Reproducible Results
THE INITIAL REPORTER COMPLAINED OF DISCREPANT RESULTS FOR 2 SAMPLES FROM 1 PATIENT TESTED FOR ELECSYS CMV IGG (CMV IGG) ON A COBAS E 801 ANALYTICAL UNIT WHEN COMPARED TO COMPETITOR METHODS. THE PATIENT WAS FIRST TESTED ON (B)(6) 2026 WITH THE FOLLOWING RESULTS: THE RESULT FROM THE E801 ANALYZER WAS 1.27 IU/ML (POSITIVE). THE RESULT FROM THE ABBOTT METHOD WAS 68.7 UA/ML (POSITIVE). THE RESULT FROM THE DIASORIN METHOD WAS 88.6 U/ML (POSITIVE). THE CMV IGG AVIDITY RESULT FROM THE VIDAS METHOD WAS 43% (MODERATE). THE DIASORIN PARVOVIRUS B19 RESULT WAS 54.90 U/ML (POSITIVE). A NEW SAMPLE WAS OBTAINED ON (B)(6) 2026 WITH THE FOLLOWING RESULTS: THE RESULT FROM THE E801 ANALYZER WAS 0.967 IU/ML (INDETERMINATE). THE RESULT FROM THE ABBOTT METHOD WAS 77.8 UA/ML (POSITIVE). THE CMV IGG AVIDITY RESULT FROM THE VIDAS METHOD WAS 45% (MODERATE). A NEW SAMPLE WAS OBTAINED ON (B)(6) 2026 WITH THE FOLLOWING RESULTS: THE RESULT FROM THE E801 ANALYZER WAS 0.590 IU/ML (INDETERMINATE). THE RESULT FROM THE ABBOTT METHOD WAS 79 UA/ML (POSITIVE). THE RESULT FROM THE DIASORIN METHOD WAS 90.8 U/ML (POSITIVE). THE CMV IGG AVIDITY RESULT FROM THE VIDAS METHOD WAS 46% (MODERATE).
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24818675 ↗MalfunctionMar 9, 2026High Test Results; Non Reproducible Results
THE INITIAL REPORTER RECEIVED A QUESTIONABLE POSITIVE ELECSYS CMV IGG RESULT FROM ONE PATIENT SAMPLE TESTED ON THE COBAS E 801 ANALYTICAL UNIT. ON (B)(6) 2026: THE INITIAL RESULT OF THE INITIAL PATIENT SAMPLE COLLECTED ON (B)(6) 2026 WAS 7.69 U/ML (POSITIVE). ON (B)(6) 2026: THE REPEAT RESULT OF THE INITIAL PATIENT SAMPLE FROM ANOTHER ANALYZER WAS <0.150 U/ML WITH A DATA FLAG (NEGATIVE). ON (B)(6) 2026, A NEW SAMPLE WAS OBTAINED, AND THE RESULT FROM THE OTHER ANALYZER WAS <0.150 U/ML WITH A DATA FLAG (NEGATIVE).
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24552078 ↗MalfunctionJan 15, 2026False Positive Result; High Test Results; Non Reproducible Results
THERE WAS AN ALLEGATION OF QUESTIONABLE ELECSYS CMV IGG RESULTS FROM THE COBAS E 801 MODULE. THE INITIAL RESULT WAS 7.57 U/ML (REACTIVE). THE REPEAT RESULT WAS CONSISTENTLY 0.15 U/ML (NON-REACTIVE) UPON TESTING FIVE TIMES.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24077914 ↗MalfunctionJan 14, 2026False Negative Result; Low Test Results
THERE WAS AN ALLEGATION OF A FALSE NEGATIVE ELECSYS CMV IGG RESULT FROM THE COBAS E 801 ANALYTICAL UNIT FOR ONE PATIENT. PLEASE SEE THE ATTACHMENT "(B)(6)" FOR THE PATIENT'S RESULTS.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24067106 ↗MalfunctionDec 11, 2025Low Test Results; Non Reproducible Results; Low Test Results; Non Reproducible Results
THERE WAS AN ALLEGATION OF QUESTIONABLE ELECSYS CMV IGG RESULTS FROM THE COBAS E 801 MODULE. THE RESULT FOR A DONOR SAMPLE MEASURED ON (B)(6) 2025, HAD A RESULT OF < 0.150 U/ML WITH A DATA FLAG (NON-REACTIVE). TESTING OF BOTH EXISTING RETENTION SAMPLES FROM THE SAME DONOR/SAME DRAW HAD A RESULT OF > 500 U/ML WITH A DATA FLAG (REACTIVE). THE REPEAT RESULT WAS EXPECTED DUE TO EARLIER SCREENING RESULTS FOR THIS DONOR.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 23778187 ↗MalfunctionDec 3, 2025High Test Results; High Test Results
THE INITIAL REPORTER QUESTIONED A HIGH RESULT FOR 1 PATIENT SAMPLE TESTED FOR ELECSYS CMV IGG (CMV IGG) ON A COBAS E 801 ANALYTICAL UNIT. THE INITIAL CMV IGG RESULT FROM THE E801 ANALYZER WAS 12.1 U/ML (POSITIVE). FOR CONFIRMATION, THE SAMPLE WAS SENT TO 2 EXTERNAL LABORATORIES, WHERE THE CMV IGG RESULTS FROM 3 COMPETITOR METHODS WERE: ABBOTT ALINITY: < 6 (UNIT OF MEASURE NOT PROVIDED); NEGATIVE. DIASORIN LIAISON: < 5 (UNIT OF MEASURE NOT PROVIDED); NEGATIVE. VIDAS BIOMÉRIEUX: < 4 (UNIT OF MEASURE NOT PROVIDED); NEGATIVE. ON (B)(6) 2025, THE SAMPLE WAS REPEATED ON THE E801 ANALYZER, AND THE RESULT WAS "POSITIVE." THE SPECIFIC RESULT WAS NOT PROVIDED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 23706928 ↗MalfunctionDec 2, 2025False Negative Result; False Negative Result
THERE WAS AN ALLEGATION OF QUESTIONABLE ELECSYS CMV IGM AND ELECSYS CMV IGG RESULTS FROM ONE PATIENT FROM THE COBAS E 801 MODULE. THIS MEDWATCH IS FOR THE ELECSYS CMV IGG ASSAY. REFER TO THE MEDWATCH WITH A1 PATIENT IDENTIFIER (B)(6) FOR THE ELECSYS CMV IGM ASSAY. SAMPLE 1 (B)(6) 2025) AT 10 WEEKS OF PREGNANCY: THE ELECSYS CMV IGM RESULT WAS 0.38 COI WITH A DATA FLAG (NEGATIVE). THE ELECSYS CMV IGG RESULT WAS 0.150 U/ML WITH A DATA FLAG (NEGATIVE). ON (B)(6) 2025, THE DIASORIN LIAISON CMV IGM RESULT WAS 23.1 UA/ML (POSITIVE). THE DIASORIN LIAISON CMV IGG RESULT WAS 48 UA/ML (POSITIVE). THE DIASORIN LIAISON CMV IGG AVIDITY RESULT WAS 0.0493. THE VIDAS BIOMÉRIEUX CMV IGG RESULT WAS <6 UA/ML (GREYZONE/EQUIVOCAL). ON (B)(6) 2025, THE REPEAT ELECSYS CMV IGM RESULT USING REAGENT LOT 848029 WAS 0.40 COI (NEGATIVE). ELECSYS CMV IGG RESULT USING REAGENT LOT 836250 WAS 0.150 U/ML WITH A DATA FLAG (NEGATIVE). SAMPLE 2 (B)(6) 2025) 19 WEEKS OF PREGNANCY: THE ELECSYS CMV IGM RESULT WAS 2.72 COI. THE REPEAT RESULT WAS 2.67 COI (POSITIVE). THE ELECSYS CMV IGG RESULT WAS 10.8 U/ML. THE REPEAT RESULT WAS 10.6 U/ML (POSITIVE). ON (B)(6) 2025, THE DIASORIN LIAISON CMV IGM RESULT WAS 25.4 UA/ML (POSIT
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 23696221 ↗MalfunctionNov 5, 2025Low Test Results; Low Test Results
THE INITIAL REPORTER QUESTIONED THE RESULTS FROM MULTIPLE SAMPLES FROM 1 PATIENT TESTED FOR ELECSYS CMV IGG (CMV IGG) ON A COBAS E 801 ANALYTICAL UNIT. SAMPLE FROM (B)(6) 2025: THE CMV IGG RESULT FROM THE E801 ANALYZER WAS 0.61 U/ML (BORDERLINE). THIS SAMPLE WAS TESTED BY 2 COMPETITOR METHODS: DIASORIN LIAISON CMV IGG: 20.4 AU/ML (POSITIVE) DIASORIN LIAISON CMV IGG AVIDITY: IGG TOO LOW (AVIDITY NOT INTERPRETABLE) BIOMÉRIEUX VIDAS CMV IGG: 9 AU/ML (POSITIVE) BIOMÉRIEUX VIDAS CMV IGG AVIDITY: 8 AVI% THE RESULTS SUGGEST A RECENT PRIMARY CMV INFECTION. SAMPLE FROM (B)(6) 2025: THE CMV IGG RESULT FROM THE E801 ANALYZER WAS 0.276 U/ML (NEGATIVE). SAMPLE FROM (B)(6) 2025: ON (B)(6) 2025, THE CMV IGG RESULT WAS 0.28 U/ML (NEGATIVE). ON (B)(6) 2025, THE REPEAT RESULT WAS 0.260 U/ML (NEGATIVE). THIS SAMPLE WAS TESTED BY 2 COMPETITOR METHODS: DIASORIN LIAISON CMV IGG: 39.3 AU/ML (POSITIVE). DIASORIN LIAISON CMV IGG AVIDITY: 0.105 BIOMÉRIEUX VIDAS CMV IGG: 16 AU/ML (POSITIVE). BIOMÉRIEUX VIDAS CMV IGG AVIDITY: 28 AVI% THE RESULTS CONFIRM A RECENT PRIMARY INFECTION WITH CMV. THE CUSTOMER SUSPECTS A MISSED SEROCONVERSION OF THE ROCHE CMV IGG ASSAY.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 23478678 ↗MalfunctionNov 3, 2025Low Test Results; Low Test Results
WE RECEIVED AN ALLEGATION ABOUT DISCREPANT RESULTS FOR 1 PATIENT SAMPLE TESTED WITH ELECSYS CMV IGG ASSAY ON A COBAS E 801 ANALYTICAL UNIT. INITIAL RESULT: 0.0 U/ML (INTERPRETED AS NEGATIVE). REPEAT RESULT: 125.0 U/ML (TESTED WITH ABBOTT CMV IGG AND INTERPRETED AS POSITIVE).
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 23453463 ↗MalfunctionNov 3, 2025False Negative Result; False Negative Result
THERE WAS AN ALLEGATION OF QUESTIONABLE ELECSYS CMV IGG RESULTS WITH A PATIENT SAMPLE TESTED ON A COBAS E 801 ANALYTICAL UNIT. ON (B)(6) 2025: THE RESULT WAS NON-REACTIVE. ON (B)(6) 2025: THE RESULT WAS 235 U/ML (REACTIVE).
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 23450692 ↗
Other Roche Diagnostics GmbH products
- cobas e 411 Immunoassay Analyzer2 models · 1,218 reports
- cobas e 801 Immunoassay analyzer3 models · 713 reports · 1 recall
- CoaguChek XS PT strips2 models · 632 reports
- CoaguChek XS Patient Self Testing Care Kit2 models · 346 reports
- Elecsys FT3 III4 models · 283 reports
- Elecsys Estradiol III2 models · 162 reports
- Elecsys TSH4 models · 155 reports
- Sodium electrode3 models · 150 reports
Sources and updates
- Models: FDA GUDID, file dated Oct 13, 2026. Models are grouped by the brand name the manufacturer registered.
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page